By Fineline Cube 
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted dual-payload antibody-drug conjugate (ADC), in a Phase I clinical trial for advanced solid tumors. Developed through Innovent’s proprietary DuetTx dual-payload ADC platform, IBI3020 is the first global dual-payload ADC in its class to enter clinical development.
Clinical Trial Design
The open-label, global multi-center Phase I study is designed to assess the safety, tolerability, and preliminary efficacy of IBI3020 in advanced solid tumors. The trial will also determine the recommended Phase II dose (RP2D). The study is expected to be carried out in both China and the U.S., with recent IND approval in the latter.
Preclinical Data
Preclinical data demonstrated potent antitumor activity across multiple xenograft models. The ADC exhibited a significant bystander effect, enhancing tumor microenvironment penetration. Additionally, IBI3020 showed a favorable safety profile with controllable toxicity thresholds.-Fineline Info & Tech